Regenerative medicine for inflammatory bowel disease

• Arimura Yoshiaki

  First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan

• Nagaishi Kanna

  Department of Anatomy, Sapporo Medical University, Sapporo Medical University, Sapporo, Japan

• Naishiro Yasuyosh

  Department of Educational Development, Sapporo Medical University, Sapporo, Japan

• Yamashita Kentaro

  First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan

• Shinomura Yasuhisa

  First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan

• Imai Kohzoh

  Division of Novel Therapy for Cancer, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Abstract

Inflammatory bowel disease (IBD) is potentially curable by “immune rest” and correction of the genetic predisposition inherent in allogeneic hematopoietic stem cell transplantation. However, balancing risks against benefits remains challenging. Recently, application of mesenchymal stem cells (MSCs) serving as a site-regulated “drugstore” is a new concept which creates the possibility of an alternative treatment for many intractable diseases, such as IBD. Depending on the required function of MSC as a cell provider, immune moderator, and/or trophic resource, MSC therapy should be optimized; surprisingly, therapeutic effects do not always require full engraftment of MSCs, but rely on the capacity of MSCs to inhibit pathogenic immune responses and release trophic factors favoring tissue repair. Therefore, optimization of pleiotropic gut trophic factors produced by MSCs must directly enhance new drug discovery for IBD.<BR>Stem cell biology holds great promise for a new era of cell-based therapy, sparking considerable interest among scientists, clinicians, and their patients. However, the translational arm of stem cell science is in a relatively primitive state. Although several clinical studies using MSCs have been initiated, the early results suggest several inherent problems. In all of them, optimization of MSC therapy appears to be the most urgent problem, to be resolved only by scientifically unveiling the mechanisms of therapeutic action. The authors believe that such information would facilitate the critical steps in the paradigm shift from stem cell biology to regenerative medicine for conquering IBD in near future.

Journal

• Inflammation and Regeneration

  Inflammation and Regeneration 32 (2), 061-066, 2012

  The Japanese Society of Inflammation and Regeneration

Keywords

• hematopoietic stem cell transplantation (HSCT)
• inflammatory bowel disease (IBD)
• immune-mediated inflammatory disease (IMID)
• mesenchymal stem cells (MSCs)
• regenerative medicine

Details

• CRID: 1390282680234727552
• NII Article ID: 130004482295
• DOI: 10.2492/inflammregen.32.061
• COI: 1:CAS:528:DC%2BC38XmslKks7k%3D
• ISSN: 18808190
• ISSN: 18809693
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed